When CVS made the decision to forego tobacco sales, the estimated $2 billion in annual revenues it gave up amounts to more than twice the amount of money ACS collects in a year (The Cancer Letter, Feb. 7). However, ACS positions itself as the vanguard of tobacco control, and critics say that close association with a retailer that profits from tobacco undermines the society’s own goals and harms its brand.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
